Century Therapeutics (IPSC) Debt Ratio (2020 - 2026)

Century Therapeutics (IPSC) posted quarterly Debt Ratio of 0.01 for Q1 2026, down 64.64% quarter-over-quarter from 0.02 in Q4 2025.

Century Therapeutics (IPSC) Debt Ratio (2020 - 2026) Analysis & Trends

Century Therapeutics (IPSC) has reported Debt Ratio for 6 consecutive years, with 0.01 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.01; the TTM figure through Mar 2026 stood at 0.01 (changed N/A YoY), while the FY2025 annual figure was 0.02, changed N/A from the prior year.
Debt Ratio slipped to 0.01 in Q1 2026 per IPSC's latest filing, from 0.02 in the prior quarter.
Across five years, Debt Ratio topped out at 0.03 in Q3 2025 and bottomed at 0.01 in Q1 2026.
Historically, Debt Ratio has averaged 0.02 across 4 years, with a median of 0.02 in 2022.
Annual changes were most pronounced in 2022 — Debt Ratio decreased 7.4% — and 2023, when it gained 23.98%.
Century Therapeutics' Debt Ratio stood at 0.02 in 2022, then gained by 7.23% to 0.02 in 2023, then decreased by 25.59% to 0.02 in 2025, then plunged by 64.64% to 0.01 in 2026.
Business Quant data shows IPSC's Debt Ratio at 0.01 in Q1 2026, 0.02 in Q4 2025, and 0.03 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Century Therapeutics	346.65 Mn	86.58 Mn	-	-

Download Data